Global Women’s Health Drugs Market to 2024 – Influx of New Products Including Orilissa, Relugolix and Bremelanotide

Global Women’s Health Drugs Market to 2024 Research Report provides Key Marketed Products, Pipeline Landscape Assessment, Company Analysis and Positioning, Revenue and Market Share and Strategic Consolidations.

Pune, India - February 12, 2019 /MarketersMedia/ —

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.

The Women’s Health Market is relatively small considering the high prevalence of many women’s health indications. However, robust growth is projected over the forecast period due to the influx of a number of new products.

This report covers all indications within women’s health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.

*Company Analysis and Positioning:
Revenue and Market Share Analysis by Company
1 Bayer AG - Company to Remain a Market Leader within Women’s Health
2 AbbVie Inc - Orilissa to Reach Blockbuster Status, Boosting Company’s Market Share
3 Allergan - Revenue Gains From Fibristal, Lo Loestrin Fe and Liletta to Offset Losses from Minastrin 24 Fe and Estrace
4 Merck & Co. - Company to Remain a Key Player Due to Growth of Gardasil/Gardasil 9
5 GlaxoSmithKline - Cervarix and Retosiban to Drive Strong Growth
6 Pfizer - How will patent expiration affect revenues for women’s health market?
7 TherapeuticsMD – Women’s Health Specialist to Gain Considerable Market Share by 2024

Get Discount on Global Women’s Health Drugs Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1854865

Scope
- There are 277 pipeline products in active development for women’s health disorders. Which molecule types and molecular targets are most prominent within the pipeline?
- Merck&Co and Bayer currently represent leading companies within women’s health. Will they maintain this dominance over the forecast period?
- Gardasil, Mirena and Nuvaring and are among the most lucrative drugs within the women’s health market. Which of these will experience a considerable decline in revenue over the forecast period following loss of patent protection?
- The influx of a number of recent market entrants and late-stage pipeline products will have a considerable impact on the women’s health market over the forecast period. Which of these drugs are projected to achieve blockbuster status by 2024?
- In total, 246 licensing deals relating to women’s health products have been completed since 2006. Which types of assets attracted the largest deal values?

Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1854865

Reasons to buy:
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the women’s health pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.
- Predict growth in market size by examining multi-scenario forecasting trends from 2017 to 2024 and determine the contributions that different products and companies will make to this growth.
- Identify commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals.

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1854865-global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide-to-diversify-landscape-and-drive-growth.html

Source URL: https://marketersmedia.com/global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide/481772

Source: MarketersMedia

Release ID: 481772

More News From Business - Malaysian Talks

Thai exec guilty in poaching case, cleared of panther charge

Mar 19, 2019

BANGKOK — A Thai construction tycoon was convicted Tuesday on charges related to a high-profile poaching case last year but was found not guilty of possessing the carcass of an endangered black panther seen in photos that had sparked a public outcry. The Thong Pha Phum Provincial Court sentenced Premchai Karnasuta, the president of Italian-Thai Development PLC, to 16 months in prison for possessing the carcass of a protected Kalij pheasant, possessing firearms in public areas, and supporting others to hunt in a protected wildlife sanctuary. Premchai was arrested last February after park rangers found that he and three of...

Asia bracing for destruction by alien pest: fall armyworms

Mar 19, 2019

THA MUANG, Thailand — Fall armyworms, a longtime American pest, are munching their way around the globe, raising alarm now in Asia after entrenching themselves in Africa. Experts say the insect was first found outside the Americas in 2016, in Africa, where it has infested up to half of some crops of maize, sorghum and millet. It's now spread through Yemen and South Asia to Thailand and China. This new arrival to her territory worries Uraporn Nounart, a specialist on farm pests at Thailand's Agriculture Department. "We never had this one before. They just were found late last year and...

Orangutan mother blinded by air gun pellets in Indonesia

Mar 19, 2019

SIBOLANGIT, Indonesia — An orangutan mother has been blinded after being shot with at least 74 air gun pellets on Indonesia's Sumatra island, where threats to the endangered species have increased as the palm oil and paper industries shrink its jungle habitat. An X-ray showed at least 74 air gun pellets in her body, including four in her left eye and two in the right, said veterinarian Yenny Saraswati with the Sumatran Orangutan Conservation Program. The great ape, named "Hope" by her rescuers, also had several wounds believed to have been caused by sharp objects, she said Monday. Hope also...

Asian shares mixed in muted trading ahead of US Fed meeting

Mar 19, 2019

TOKYO — Asian shares were mixed in muted trading Tuesday as investors awaited the U.S. Federal Reserve meeting later in the week. Japan's benchmark Nikkei 225 lost 0.3 percent to 21,528.23 in early trading. Australia's S&P/ASX 200 edged down 0.1 percent to 6,182.10. South Korea's Kospi inched down less than 0.1 percent to 2,178.91. Hong Kong's Hang Seng rose nearly 0.1 percent to 29,429.99, while the Shanghai Composite gained 0.3 percent to 3,104.89. U.S. stock indexes finished modestly higher Monday, extending the market's solid gains from a rally last week. The S&P 500 gained 10.46 points, or 0.4 percent, to...

Jakarta's 1st subway to ease frustration, sweat and fumes

Mar 19, 2019

JAKARTA, Indonesia — Commuting in Indonesia's gridlocked capital will for some involve less frustration, sweat and fumes when its first subway line opens later this month. The line is the latest of infrastructure improvements nationwide that officials hope will help the giant but laggard nation catch up with its neighbors. The 16-kilometer (10-mile) system running south from Jakarta's downtown is the first phase of a development that if fully realized will plant a cross-shaped network of stations on the teeming city of 30 million people. A $2.4 billion elevated rail network linking Jakarta and its satellite cities is also taking...